Alkermes plc - Ordinary Shares (NQ:ALKS)

43.18 +1.43 (+3.43%)

Delayed Quote Updated: 3:19 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alkermes plc - Ordinary Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Happy New Year - Sunday Edition ↗

January 02, 2022

Starting a new year - we look at tech, pharma and mining stocks and their goings-on.

Via Talk Markets

Alkermes Has Launched Employee Resource Groups

December 07, 2021

SOURCE: Alkermes

Via 3BL Media

Our Collective Responsibility to Respond Effectively to the Climate Crisis

December 03, 2021

SOURCE: Alkermes

Via 3BL Media

Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2021 ↗

December 01, 2021

Upgrades Goldman Sachs upgraded the previous rating for Grupo Aeroportuario del Sureste SAB de CV

Via Benzinga

One Overdose Is Too Many

November 29, 2021

SOURCE: Alkermes

Via 3BL Media

Alkermes in Action: Giving Tuesday

November 30, 2021

SOURCE: Alkermes

Via 3BL Media

Alkermes Celebrates National Family Caregivers Month

November 24, 2021

SOURCE: Alkermes

Via 3BL Media

75 Biggest Movers From Yesterday ↗

November 10, 2021

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Check out these big penny stock gainers and losers...

Via Benzinga

Janssen Partially Terminates Nanoparticle License Agreement With Alkermes ↗

November 09, 2021

Alkermes plc (NASDAQ: ALKS) stock is trading lower after announcing that Janssen, a unit of Johnson & Johnson (NYSE: JNJ), has provided notice of its...

Via Benzinga

Why Alkermes Stock Is Sinking Today ↗

November 09, 2021

Johnson & Johnson partly ended two licensing agreements with the company.

Via The Motley Fool

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data ↗

November 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...

Via Benzinga

7 A-Rated Healthcare Stocks to Buy for the Long Haul ↗

November 01, 2021

It looks like we're on the back end of the Covid pandemic, so it's a good time to look at healthcare stocks that have a big future.

Via InvestorPlace

10 Biggest Price Target Changes For Thursday ↗

October 28, 2021

Oppenheimer lowered Teladoc Health, Inc. (NYSE:TDOC

Via Benzinga

Alkermes plc (ALKS) Q3 2021 Earnings Call Transcript ↗

October 27, 2021

ALKS earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Cyber Currency ↗

October 26, 2021

Canadian stocks are particularly buoyant and not just in energy which is a riser today because the loony is up against the buck.

Via Talk Markets

Ketamine’s Potential As A Treatment For Depression Has Drawn Major Industry Attention

October 27, 2021

Palm Beach, FL –October 27, 2021 – FinancialNewsMedia.com News Commentary – Among the race to see what psychedelic drugs can do, ketamine is a step ahead of all other drugs, because it has already been...

Via FinancialNewsMedia

Wednesday Market Coverage ↗

October 20, 2021

Today gold rose again despite the active market for bitcoin and the lower Chinese demand for mine products like iron and coal.

Via Talk Markets

The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More ↗

October 24, 2021

Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...

Via Benzinga

Beam Therapeutics Stock Flashes Renewed Technical Strength ↗

October 12, 2021

On Tuesday, Beam Therapeutics stock reached an key performance benchmark, seeing its RS Rating jump to 92, up from 88 the day before.

Via Investor's Business Daily

Innoviva Stock In Buy Range; Joins Ranks Of Top-Performing Stocks With Strength Ratings Over 90 ↗

October 08, 2021

Innoviva stock is within a buy range after climbing above a 16.82 entry in a flat base. The proper buying range is up to 5% above the entry.

Via Investor's Business Daily

Alkermes Stock Composite Rating Rises To Near-Perfect 96 As It Posts Erratic But Huge Sales Gains ↗

October 05, 2021

The IBD SmartSelect Composite Rating for Alkermes rose from 94 to 96 Tuesday.

Via Investor's Business Daily

Arcturus Therapeutics Stock Sees Relative Strength Rating Rise To 83 ↗

September 29, 2021

Arcturus Therapeutics sees its Relative Strength Rating hit the 80-plus level.

Via Investor's Business Daily

Ligand Pharmaceuticals Stock Shows Rising Price Performance ↗

September 22, 2021

A Relative Strength Rating upgrade for San Diego-based Ligand Pharmaceuticals stock shows improving technical performance.

Via Investor's Business Daily

Acceleron Pharma Stock Meets 80-Plus Relative Strength Rating Benchmark ↗

September 22, 2021

Want to build a watch list? Focus on stocks with an 80-plus RS Rating. Acceleron Pharma stock cleared that benchmark with an upgrade to 83.

Via Investor's Business Daily

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs ↗

October 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)...

Via Benzinga

The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug ↗

September 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks...

Via Benzinga

Inmune Bio Stock Flashes Robust RS Rating ↗

September 22, 2021

On Wednesday, Inmune Bio stock saw its Relative Strength Rating jump into the 90-plus percentile, to 92 from 85 the day before.

Via Investor's Business Daily

New Survey Provides Insights Into Drinking Behaviors During the Pandemic

September 22, 2021

SOURCE: Alkermes

Via 3BL Media

Recovery Month Renews Focus on Diagnosis, Treatment of Substance Use Disorder

September 21, 2021

SOURCE: Alkermes

Via 3BL Media

Topics Death

Ligand Pharmaceuticals Stock Shows Market Leadership With Jump To 82 RS Rating ↗

September 20, 2021

Ligand Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 71 to 82.

Via Investor's Business Daily

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.